People · Operator
Named in public records as an officer, director or promoter · active 2023–2024 · Other, Pharma, Biotechnology, AI / ML
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ascend Advanced Therapies Group, Inc. | — | Other | Series D+ | $130.6M | $1.2B | 2024 |
| Soleno Therapeutics Inc | — | Pharma | Series C | $98.6M | $680.6M | 2023 |
| Ascend Gene & Cell Therapies Ltd. | — | Other | Series C | $66.6M | $680.9M | 2023 |
| Entact Bio, Inc. | — | Biotechnology | Series C | $40.3M | $426.8M | 2024 |
| ML LAF Pref Sidecar, LLC | — | AI / ML | Seed | $3.1M | $26.4M | 2023 |
Andrew Sinclair at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Sinclair on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Fred Cohen | 2 | 12 |
| Balaji Muralidhar | 2 | 3 |
| Timothy Funnell | 2 | 2 |
| Michael Beecham | 2 | 2 |
| Ernest Mario | 1 | 9 |
| William Harris | 1 | 9 |
| Alon Lazarus | 1 | 7 |
| Richard Gaster | 1 | 7 |
| Rajen Dalal | 1 | 5 |
| Edgar G Engleman | 1 | 5 |
| Matthew Pauls | 1 | 4 |
| Eric Shiozaki | 1 | 4 |
| Anna French | 1 | 3 |
| Mahendra D. Shah | 1 | 2 |
| Steinar Engelsen | 1 | 2 |
| Steinar J Engelsen | 1 | 2 |
| Anish Bhatnagar | 1 | 2 |
| Andrew May | 1 | 2 |
| William G. Harris | 1 | 2 |
| William Hawkins | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.